EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, AVXL: Anavex Lf SC

06 Nov 25 17:20
LAST:

7.400

CHANGE:
 0.09		OPEN:
7.300		HIGH:
7.590		ASK:
4.480		VOLUME:
1.14M
CHG(%):
1.23		PREV:
7.310		LOW:
7.220		BID:
3.860		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
06 Nov 257.3007.5907.2207.4001.14M
05 Nov 257.4007.5107.2707.3101.55M
04 Nov 257.6507.7907.4407.4701.03M
03 Nov 257.9007.9387.4507.7401.66M
31 Oct 258.0508.1407.8507.9701.35M
30 Oct 258.0008.3507.9808.030805.8K
29 Oct 258.1008.3207.8808.0201.54M
28 Oct 258.4308.4508.0608.1001.24M
27 Oct 258.7008.7908.3508.4901.06M
24 Oct 258.8108.9678.5808.615804.6K

COMPANY PROFILE

Name:Anavex Lf SC
About:Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against the Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
Sector:Healthcare
Industry:Biotechnology
Address:630 5th Avenue, New York, NY, United States, 10111
Website:https://www.anavex.com
CUSIP:032797102
CIK:0001314052
ISIN:US0327973006
FIGI:BBG000C9K8K4
LEI:549300K1I5L8COCQ8W36

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:7.582.4%
MA10:7.917.0%
MA20:8.4814.6%
MA50:8.9020.2%
MA100:9.6931.0%
MA200:9.1623.8%
STO9:6.08 
STO14:4.11 
RSI14:18.90 
WPR14:-95.61 
MTM14:-1.96
ROC14:-0.21 
ATR:0.42 
Week High:8.3512.8%
Week Low:7.222.5%
Month High:10.3840.3%
Month Low:7.2223.8%
Year High:14.4495.1%
Year Low:7.163.4%
Volatility:5.70 

RECENT SPLITS

Date Ratio
07 Oct 20151-4